Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 6/20 | 0.51 |
| ▸ | TOP1 | P11387 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 5/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7236603 | 0.80 | PDE4D (0.61) | PDE4DTOP1PDE4APDE4BBCHE | |
| SCHEMBL27652747 | 0.79 | PDE4D (0.53) | PDE4DTOP1PDE4APDE4BBCHE | |
| SCHEMBL23293733 | 0.79 | MAP4K4 (0.59) | PDE4DTOP1PDE4APDE4BBCHE | |
| Bromide SCHEMBL7230528 | 0.79 | PDE4D (0.60) | PDE4DTOP1PDE4APDE4BBCHE | |
| SCHEMBL10431290 | 0.79 | PDE4D (0.51) | PDE4DTOP1PDE4APDE4BBCHE | |
| SCHEMBL10431289 | 0.79 | PDE4D (0.51) | PDE4DTOP1PDE4APDE4BBCHE | |
| SCHEMBL7445324 | 0.78 | PDE4D (0.71) | PDE4DTOP1PDE4APDE4BBCHE | |
| SCHEMBL27704588 | 0.78 | ALDH1A1 (0.51) | PDE4DTOP1PDE4APDE4BBCHE | |
| SCHEMBL8353332 | 0.78 | MEN1 (0.54) | MAPTALDH1A1NPSR1KMT2AMEN1 | |
| SCHEMBL2082002 | 0.77 | PDE4D (0.51) | PDE4DTOP1PDE4APDE4BBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-2043646-B1 | (E)-N-{3-(8-Chloro-11H-10-oxa-1-aza- dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-phenyl} -methanesulfonamide as a GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | LILLY CO ELI (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8101760-B2 | Glucocorticoid receptor modulator and methods of use | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100069425-A1 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| WO-2008008882-A2 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 2008-01-17 | — | — | WO | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | PDE4D 1580/4885TOP1 1381/4885PDE4A 1676/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | PDE4D 1149/4885TOP1 2915/4885PDE4A 1202/4885 |
| US-20100069425-A1 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | NR3C1, NR3C2, MC2R | PDE4D 1385/4885TOP1 1554/4885PDE4A 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.